Toll-like receptors (TLRs) play an essential role in defense responses. Immune cells express multiple TLRs which are simultaneously activated by microbial pathogens. PRotein Associated with Tlr4 A (PRAT4A) is a chaperone-like endoplasmic reticulum (ER)-resident protein required for the proper subcellular distribution of multiple TLRs. PRAT4A
Introduction
Toll-like receptors (TLRs) serve as the first line of defense against microbial infection. TLRs directly recognize microbial components and mount innate immune responses (1, 2) . Because single microbes or viruses express a variety of TLR ligands, immune cells express multiple TLRs which are simultaneously activated in response to pathogens. It is therefore important to coordinate the expression and responsiveness of TLRs in individual cells for appropriate immune responses against pathogens. Without a control determining the strength of total TLR responses, insufficient or excessive activation of TLRs may exacerbate microbial infection or induce autoimmune diseases (3, 4) .
Chaperons may have a role in determining the strength of combined responses of multiple TLRs. gp96, for example, regulates the activity of multiple TLRs. Macrophages lacking gp96 are hyporesponsive to a variety of TLR ligands (5) . Recently, we had reported a novel molecule PRotein Associated with Tlr4 A (PRAT4A) chaperoning multiple TLRs. PRAT4A was first identified as a molecule that is associated with TLR4 (6) . PRAT4A was later shown to be associated with TLR1 and TLR9 and be required for the responses of TLR1, TLR2, TLR4, TLR7 and TLR9 (7) . PRAT4A gene silencing impaired trafficking of TLR2 and TLR4 to the cell surface and ligand-induced TLR9 trafficking to endosome/lysosome from the endoplasmic reticulum (ER). Bone marrow dendritic cells (BM-DCs)/macrophages from PRAT4A À/À mice have shown impaired cytokine production to whole bacteria (7) . Interestingly, PRAT4A mRNA expression was down-regulated upon TLR stimulation, whereas mRNA-encoding gp96, a general chaperone required for TLRs, was not altered by TLR stimulation (7) . Down-regulation of PRAT4A may lead to not only decrease in TLR responsiveness but also alteration in the relative contribution of each TLR to the combined TLR response since PRAT4A dependency varies between TLRs. Among nucleotide-sensing intracellular TLRs, TLR3 responses are not altered, while TLR7/9 responses are completely blunted in PRAT4A À/À BM-DCs. Despite impaired cytokine production, activation of TLR2/4 signaling pathways is still detectable in PRAT4A À/À BM-DCs (7) . This implies a partial dependence of these TLRs on PRAT4A.
These results suggest that PRAT4A has a great influence on combined TLR responses. It is interesting and important to see how PRAT4A interacts with each TLR. In the present study, TLR2/4 chimeric molecule and PRAT4A mutants were employed to address this issue and revealed differential interaction of PRAT4A with multiple TLRs.
Methods

PRAT4A
À/À mice and bone marrow chimeric mice PRAT4A À/À mice and bone marrow (BM) chimeric mice were generated as previously described (7) . All animal experiments were conducted with the approval of the Animal Research Committee at the Institute of Medical Science, The University of Tokyo.
MD2, PRAT4A mutants, TLR4/TLR2 chimeras and TLR4 mutants
Murine PRAT4A cDNA was cloned into retroviral vectors, pMX-neomycin and -puromycin. The stop codon of PRAT4A was replaced with the HA epitope. PRAT4A mutants [R95L, M145K and S231I, reported in the single-nucleotide polymorphism (SNP) database (http://www.ncbi.nlm.nih.gov/ SNP/), rs34394157, rs1063251 and rs9471969, respectively] were generated by using the QuickChange Site-Directed Mutagenesis Kit from Stratagene (Cedar Creek, TX, USA). The stop codons of PRAT4A and its mutants were replaced with the Flag epitope. Murine MD-2 cDNA was cloned into pEF-BOS expression vector. The stop codon of MD-2 was replaced with the Flag epitope. Human TLR4/TLR2 chimeras and mutant TLR4 cDNAs were generated and described previously (8) .
Cells
TLR1/2/3/4/7/9-green fluorescent protein (GFP) were cloned into a pMX-puromycin retroviral vector and transduced into the B cell line M12.4.5. The stop codons of TLRs were replaced with the GFP epitope. BM-DCs were prepared as previously described (6, 9) . Briefly, BM cells were isolated from PRAT4A À/À or PRAT4A +/À BM chimeric mice that had been injected intra-peritoneally 4 days before with 5 mg 5-fluorouracil. After 48 h of culture, cells were transduced with retroviral vector on two successive days. After the second transduction, cells were washed and cultured in the presence of granulocyte macrophage colony-stimulating factor (GM-CSF) (10 ng ml
À1
). During BM-DC induction, puromycin (2.0 lg ml
) was included to enrich BM-DCs expressing PRAT4A. HEK293 cells were transfected with expression vectors encoding TLR2, TLR4, TLR2/4 chimeras and TLR4 mutants along with Flag-tagged PRAT4A by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
Small interfering RNA
To silence mouse PRAT4A expression, a retroviral vector pSSCH (provided by H. Iba and T. Mizutani, The University of Tokyo, Tokyo, Japan) expressing short hairpin (sh) RNA, as previously described, was used (6). The target sequence was 5#-gagtttgaagaggtgattgag-3#. This retroviral vector expressing shPRAT4A was transduced into M12.4.5 cells expressing TLR9-GFP. For complementation of PRAT4A gene silencing, four silent mutations were introduced in the target sequence (5#-gagttcgaggaagtaattgag-3#) to avoid gene silencing. PRAT4A-Flag and their mutants were cloned into a pMX-neomycin retroviral vector and transduced into M12.4.5 cells expressing TLR9-GFP and shPRAT4A (7).
Reagents
Anti-Flag mAb (M2) and M2-agarose were purchased from Sigma-Aldrich (St Louis, MO, USA). Rabbit anti-mouse PRAT4A polyclonal antibody (pAb) was established in our laboratory and described previously (7) . Mouse anti-mouse PRAT4A mAb was established in our laboratory and will be described elsewhere. Briefly, PRAT4A
À/À BALB/c mice were immunized with purified PRAT4AFH protein, BaF/3 cells expressing PRAT4A fused with a transmembrane domain enabling cell-surface expression, and PRAT4A-GST fusion protein. Cells from spleen cell were fused with SP2/0 myeloma cells, and positive clones were screened by cell-surface staining of Ba/F3 cells used for immunization. Anti-PRAT4A mAb was purified from ascites obtained from ICR-nu/nu mice.
Rat anti-GFP mAb and rat anti-mouse TLR2 mAb were both established in our laboratory. Rats were immunized with normal rat kidney cells expressing TLR9-GFP or with TLR2-GST fusion protein. One week later, cells from draining lymph nodes were fused with SP2/0 myeloma cells. Anti-GFP mAb and anti-mouse TLR2 mAb were purified from ascites obtained from ICR-nu/nu mice. Rabbit anti-mouse MD-2 serum was established by immunized rabbits with the MD-2 peptide of (HDDDYSFCRALK). Anti-HA mAb (3F10) was purchased from Roche (Mannheim, Germany). AntiGrb2 pAb was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-IkBa pAb was purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-JNK1&2 mAb(G7) was purchased from Invitrogen. The antibodies for flow cytometry [anti-TLR2 (6C2), anti-CD40 (1C10) and anti-CD86 (GL1)] were purchased from eBioscience (San Diego, CA, USA). Anti-CD11c (HL3) was purchased from BD Biosciences (Franklin Lakes, NJ, USA). Rat anti-mouse TLR4 mAb (Sa15-21) and rat anti-mouse CD14 mAb (Sa14-2) were established in our laboratory as described previously (10) . Lipid A purified from Salmonella minnesota (Re-595) was purchased from Sigma-Aldrich. CpG-B (TCCATGACGTTCCTGATGCT) and its derivatives were synthesized by Hokkaido System Science (Sapporo, Japan). Pam3CSK4 was purchased from EMC Microcollections (Tuebingen, Germany).
Flow cytometry
Cell-surface staining and analysis on a FACSCalibur (BD Biosciences) was performed as previously described (6 
Immunofluorescence
Cells were plated on a glass-bottomed dish (Matsunami glass, Osaka, Japan) and used for staining. In some experiments, CpG-rhodamine (Hokkaido System Science) was used to stimulate TLR9-GFP. To analyze the location of the TLR9-GFP fusion proteins, cells were stained with ER tracker red (Invitrogen). TLR9-GFP and markers were visualized with confocal microscopy (LSM5 PASCAL; Carl Zeiss, Inc., Tokyo, Japan).
Immunoprecipitation and immunoprobing
Cells were lysed on ice for 15 min with lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 10 lg ml À1 aprotinin, 10 lg ml ml À1 leupeptin, 1 mM PMSF and 1% Triton X-100. Lysates were separated from debris by centrifuging at 13 000 r.p.m. at 4°C for 15 min and then incubated with antibody-conjugated beads at 4°C for 2 h with rotation. Beads were washed with diluted lysis buffer for three times, and bound proteins were boiled at 100°C for 5 min in the sample buffer [0.125 M Tris-HCl (pH 6.8), 20 % glycerol, 4% SDS, 10% 2-mercaptoethanol and 0.005% bromophenol blue]. Samples were subjected to SDS-PAGE and western blotting. Reagents used for immunoprobing were anti-Flag (M2) mAb, anti-GFP mAb, anti-mouse TLR2 mAb and anti-mouse PRAT4A pAb or mAb. The second antibodies were goat anti-mouse IgG-alkaline phosphatase conjugate, goat anti-rat IgG-alkaline phosphatase conjugate (American Qualex, San Clemente, CA, USA) and goat anti-rabbit IgG-alkaline phosphatase conjugate (Bio-Rad Laboratories, Hercules, CA, USA).
Results
Association of endogenously expressed PRAT4A is detectable only with TLR4
We first examined TLR interaction with endogenously expressed PRAT4A. We established the M12.4.5 B cell lines stably expressing one of the TLRs, TLR1, TLR2, TLR3, TLR4, TLR7 or TLR9, all of which had been tagged with GFP. TLR-GFP was precipitated with anti-GFP mAb, and coprecipitation of endogenous PRAT4A was detected by immunoprobing with anti-PRAT4A mAb. We confirmed that the expression of endogenous PRAT4A was not altered by over-expression of TLRs (Fig. 1, bottom) . Although the amount of precipitated TLR protein varied between TLRs, co-precipitation of PRAT4A was detected only with TLR4 ( Fig. 1, middle) . To detect PRAT4A interaction with TLR2 and TLR9, both PRAT4A and TLR2/9 need to be overexpressed by using transient expression system in HEK293 cells as shown below (Fig. 3B ).
The TLR4 region E24-F54 is critical for PRAT4A binding PRAT4A interaction with TLR4 is much more evident than that with the rest of the TLRs studied. To further confirm these results and locate the region of TLR4 responsible for this robust interaction with PRAT4A, we employed TLR2/4 chimeric protein ( Fig. 2A ). TLR2 interaction with endogenous PRAT4A was hardly detectable (Fig. 1) . We took the advantage of this difference between TLR2 and TLR4 to locate the PRAT4A binding site on TLR4. TLR2/4 chimeras were previously used for locating the TLR4 region important for interaction with MD-2 (8, 11). The expression vectors encoding wild-type (wt) TLR4, wt TLR2 and TLR2/4 chimeras were transfected with that encoding PRAT4A into HEK293 cells. The Flag-tagged TLR proteins were immunoprecipitated and co-precipitation of HA-tagged PRAT4A was detected by anti-HA mAb. Co-precipitation of PRAT4A with wt TLR4 was detectable, whereas much smaller amount of PRAT4A was co-precipitated with wt TLR2 (Fig. 2B, compare lanes 1 and  2) . In the TLR4/2a chimera, only the N-terminal 31 amino acids (aa) were derived from TLR4 when a signal peptide was cleaved off. Nonetheless, PRAT4A was co-precipitated more with TLR4/2a than with TLR4, (Fig. 2B, lanes 2 and 3) . For unknown reason, TLR4/2a expression was always higher than that of TLR4, which would explain higher amount of PRAT4A co-precipitated with TLR4/2a than with TLR4 (Fig.  2B, lanes 2 and 3) . Among TLR2/4 chimeras, TLR4/2b, c, d were roughly equivalent to TLR4 in their expression and in PRAT4A co-precipitation. By contrast, TLR2/4a was distinct from the rest of the chimeras in that PRAT4A co-precipitation was much weaker. In the opposite direction, the HA-tagged PRAT4A protein was immunoprecipitated with anti-HA mAb. Co-precipitated TLRs were detected by immunoprobing with anti-Flag mAb. Co-precipitation of TLR4 and the four TLR2/4 chimeras (TLR4/2a, TLR4/2b, TLR4/2c and TLR4/2d) were much more evident than that of TLR2 or TLR2/4a (Fig. 2B,  lanes 8-14) . Again, TLR4/2a was co-precipitated with PRAT4A, despite the short (31 aa) TLR4-derived region. These results confirmed that PRAT4A association with TLR4 is much stronger than that with TLR2 and identified the 31 aa (E24-F54) region as the TLR4 extracellular domain important for the strong interaction with PRAT4A.
Coincidentally, this region is quite similar to the previously reported region important for MD-2 binding (E24-P34) (8, 11) . To further locate the PRAT4A binding site and compare it with the MD-2-binding site, we used additional TLR4 mutants in which C29 or C40 was replaced with alanine (TLR4-C29A and TLR4-C40A) (8, 11) . Both TLR4 mutants were reported to be defective in association with MD-2 (8, 11). PRAT4A co-precipitation was detectable with both of the TLR4 mutants, and co-precipitations of these TLR4 mutants with PRAT4A were also detectable (Fig. 2C ), demonstrating the difference between MD-2 and PRAT4A in association with TLR4. To ask whether PRAT4A competes with MD-2 for association with TLR4, we studied the effect of PRAT4A overexpression on MD-2 association with TLR4. TLR4 was immunoprecipitated and co-precipitated MD-2 was detected by immunoprobing. PRAT4A over-expression had no effect on MD-2 co-precipitation with TLR4 (Fig. 2D , compare lanes 3 and 4 in the middle panel). PRAT4A did not interfere with MD-2 interaction with TLR4. These results suggest that PRAT4A is distinct from MD-2 in its binding to TLR4, although their binding sites are close to each other.
TLR9 is distinct from TLR4 or TLR2 in association with PRAT4A
To further study differences between TLRs in interaction with PRAT4A, PRAT4A mutants were employed. We previously showed that the C-terminal region (from E257 to L276) of PRAT4A was dispensable for the responses of multiple TLRs in PRAT4A À/À BM-DCs (7, 12) . We studied additional PRAT4A mutants. In this regard, human PRAT4A SNPs (SNP: R95L, M145K and S231I) reported on the SNP database (http://www.ncbi.nlm.nih.gov/SNP/) are particularly interesting since a human SNP causing PRAT4A malfunction might be associated with susceptibility to infectious diseases. All the aa changed by SNPs are conserved between humans and mice (Fig. 3A) . Three mouse PRAT4A mutants harboring one of the SNPs were prepared and used for further analyses.
The expression vectors encoding Flag-tagged PRAT4A and its mutants were transfected into HEK293 cells together with the vectors encoding TLR-GFP. TLRs were immunoprecipitated with anti-GFP mAb, and co-precipitated PRAT4A was detected by immunoprobing with anti-Flag mAb. TLR2 or TLR4 was co-precipitated with wtPRAT4A, PRAT4A-R95L and PRAT4A-S231I but much less with PRAT4A-M145K. In the opposite direction, Flag-tagged PRAT4A proteins were immunoprecipitated with anti-Flag mAb. Co-precipitated TLRs were detected by western blot analysis using anti-GFP mAb. All the PRAT4A mutants except PRAT4A-M145K were co-precipitated with TLR2 or TLR4 as much as wtPRAT4A (Fig. 3B, top and middle, respectively) . PRAT4A-M145K was impaired in association with TLR2 or TLR4. By contrast, TLR9 was co-precipitated with all the PRAT4A mutants and all the PRAT4A mutants were co-precipitated with TLR9 (Fig. 3B, bottom) . PRAT4A-M145K mutant was not distinct from other PRAT4A mutants in association with TLR9. These results revealed that TLR9 is distinct from TLR2 or TLR4 in its way associating with PRAT4A.
The effect of PRAT4A mutants on cell-surface expression of TLR2 and TLR4/MD-2
We next studied the effect of PRAT4A mutation on cellsurface expression of TLR2 and TLR4 on BM-DCs. Stem cell-enriched BM cells were transduced with retroviral vector encoding PRAT4A or its mutants. After transduction, BM cells were cultured with GM-CSF for BM-DC induction. Expression of PRAT4A and its mutants was examined by immunoprecipitation and immunoprobing with mAb to the Flag epitope, which had been tagged at the C-terminus of PRAT4A and its mutants. Flag-tagged PRAT4A was detected in the cell lysates from PRAT4A À/À BM-DCs (Fig. 4A ). PRAT4A À/À BM-DCs were indistinguishable from wt BM-DCs with regard to proliferation in the presence of GM-CSF and expression of cell-surface markers such as CD11c and CD14 (Fig. 4B) . Enforced expression of PRAT4A mutants did not alter cell-surface expression of CD11c and CD14, indicating that BM-DC maturation is not affected by expression of PRAT4A mutants. As reported previously (7), cellsurface expression of TLR2 and TLR4/MD-2 was impaired in PRAT4A À/À BM-DCs, and the defect was apparently rescued by wtPRAT4A, although the recovery of cell-surface TLR4/ MD-2 was much less apparent than that of TLR2 (Fig. 4B) . A comparable effect was seen by the expression of two PRAT4A mutants, R95L and S231I. PRAT4A-M145K was distinct from wt or the other two PRAT4A mutants. Despite the impaired association with TLR2 (Fig. 3B ), PRAT4A-M145K was able to complement cell-surface expression of TLR2, although less effective than wt PRAT4A or the other two PRAT4A mutants (Fig. 4B) . Little, if any, complementation was seen in cell-surface expression of TLR4/MD-2 in PRAT4A À/À BM-DCs expressing PRAT4A-M145K. TLR4/MD-2 is more sensitive to the M145K mutation than TLR2.
The complete lack of TLR9 response in PRAT4A À/À BM-DCs expressing PRAT4A-M145K
We next analyzed production of cytokines including IL-6, RANTES, TNF-a and IL-12 in response to TLR2/TLR1 ligand Pam3CSK4, TLR4/MD-2 ligand lipid A or TLR9 ligand CpG-B. All the cytokine production in response to these TLR ligands were all impaired in PRAT4A À/À BM-DCs and rescued by expression of wtPRAT4A, PRAT4A-R95L or PRAT4A-S231I (Fig. 5A-C) . The PRAT4A-M145K mutant was much less effective than other mutants in complementing cytokine responses. In keeping with cell-surface expression of TLR2 and TLR4/MD-2, cytokine production in response to TLR1/TLR2 ligand Pam3CSK4 was partially but appreciably complemented by PRAT4A-M145K (Fig. 5A) , whereas the PRAT4A-M145K mutant little, if at all, influenced lipid A-induced cytokine production in PRAT4A À/À BM-DCs (Fig. 5B) . Furthermore, despite physical association of PRAT4A-M145K with TLR9, CpG-B responses in PRAT4A À/À BM-DCs were not rescued at all by expression of PRAT4A-M145K (Fig. 5C ). Physical association of PRAT4A-M145K with TLR9 seems to be insufficient for rescuing TLR9 response.
Trafficking and signaling of TLR9 in cells expressing PRAT4A-M145K
Because PRAT4A-M145K is able to associate with TLR9 (Fig. 3B) , TLR9 function may be only partially impaired. To address this possibility, TLR9 signaling was studied. For this purpose, we established the PRAT4A-silenced M12.4.5 B cell lines expressing TLR9-GFP. This M12.4.5 B cell line was transduced with retroviral vector encoding wtPRAT4A or mutant PRAT4A-M145K. Silent mutations had been introduced in the cDNAs encoding PRAT4A or its mutants to avoid gene silencing. PRAT4A gene silencing and expression of transfected PRAT4A were confirmed by immunoprobing of cell lysates with anti-PRAT4A mAb (Fig. 6A) . Endogenous PRAT4A was not detected in PRAT4A-silenced cells (lanes 2-4) , and Flag-tagged PRAT4A, which was a little slower in migration in SDS-PAGE than endogenous PRAT4A, was detected in cells expressing cDNAs encoding wtPRAT4A or PRAT4A-M145K (Fig. 6A, lanes 2 and 4, respectively) . After stimulation of these cells with CpG-B, Jun N-terminal kinase (JNK) phosphorylation and IKBa degradation was examined. While JNK phosphorylation and weak IKBa degradation were detected in M12.4.5 cells upon CpG-B stimulation (Fig. 6B, upper left) , PRAT4A gene silencing completely abolished CpG-B-induced JNK phosphorylation and IKBa degradation (Fig. 6B, upper right) . The lack of TLR9 signaling was rescued by expression of wtPRAT4A but not by PRAT4A-M145K mutant (Fig. 6B, lower panels) .
We previously reported that ligand-induced TLR9 trafficking from the ER to endosome/lysosome is defective in PRAT4A-silenced cells (7) . Since the CpG-dependent TLR9 signaling and cytokine production were both completely abolished in PRAT4A-silenced cells expressing PRAT4A-M145K (Figs 5C and 6B), CpG-B-induced TLR9 trafficking was examined. In the absence of CpG-B stimulation, TLR9-GFP co-localized with an ER marker in PRAT4A-silenced M12.4.5 cells expressing a control vector, wtPRAT4A or PRAT4A-M145K (Fig. 6Ca-c) . TLR9-GFP relocated outside the ER after CpG-B stimulation and no significant merge between the ER marker and TLR9-GFP was seen in PRAT4A-silenced M12.4.5 cells expressing wtPRAT4A (Fig. 6Ce) . Relocated TLR9 merged with its ligand CpG-B (Fig. 6Ch) . By contrast, TLR9-GFP remained in the ER in PRAT4A-silenced cells expressing a control vector or PRAT4A-M145K ( Fig. 6Cd and f) , and no merge was seen between CpG-B and TLR9-GFP (Fig. 6Cg and i) . PRAT4A-M145K was unable to rescue ligand-induced TLR9 trafficking. Defective TLR9 trafficking explained the complete lack of TLR9 signaling in M12.4.5 cells expressing PRAT4A-M145K (Fig. 6B) since TLR9 failed to encounter its ligand CpG-B (Fig. 6Ci) .
Discussion
The present study has revealed that PRAT4A interacts more strongly with TLR4 than with other TLRs. By using chimeric proteins between strongly interacting TLR4 and weakly interacting TLR2, we located the region of TLR4 which is responsible for robust binding to PRAT4A. The region E24-F54 of TLR4 was sufficient for changing weak interaction into strongly interaction (Fig. 2B, TLR4/2a mutant, lanes 2 and  9) , indicating that the TLR4 region E24-F54 has a critical role in the ability of TLR4 to strongly associate with PRAT4A. Coincidentally, this region includes the binding site for MD-2. PRAT4A is, however, unlikely to share the binding site on TLR4 with MD-2 since additional TLR4 mutants (TLR4-C29A and TLR4-C40A) interact with PRAT4A but not with MD-2 (Fig. 2C) . When PRAT4A was immunoprecipitated, both MD-2 and TLR4 were co-precipitated, indicating the trimolecular complex consisting of TLR4/MD-2/PRAT4A (6). Moreover, PRAT4A over-expression does not affect MD-2 co-precipitation with TLR4 (Fig. 2D) . PRAT4A unlikely competes with MD-2 interaction with TLR4. MD-2 was shown to be important for ligand binding and ligand-dependent TLR4 clustering (10, 13, 14) , which was confirmed by the structure of MD-2 and TLR4/MD-2 (15, 16) . Given the close proximity of PRAT4A to MD-2 on the TLR4 molecule, PRAT4A might have a regulatory role in ligand binding and TLR4 dimerization in the ER.
Two possibilities may be able to explain the strong interaction between TLR4 and PRAT4A. First, TLR4 has two binding site for PRAT4A and the E24-F54 region may be the second binding site unique to TLR4. Second, this binding site is shared with the corresponding region of TLR2 but the affinity of this site on the TLR4 molecule is much higher than that of TLR2. The results with PRAT4A-M145K mutant support the second possibility. Association of this PRAT4A mutant with TLR4 and TLR2 were both impaired (Fig. 3B) , suggesting a similarity between TLR2 and TLR4 with regard to their interaction with PRAT4A. PRAT4A-M145K mutant has further revealed that TLR9 is likely to use a distinct binding site on PRAT4A since TLR9 is still able to bind to PRAT4A-M145K (Fig. 3B) . TLR9 is distinct from TLR2 or TLR4 in that TLR9 resides in the ER and does not traffic to the cell surface but to endosome/lysosome upon ligand stimulation. PRAT4A association might reveal another difference between cellsurface TLR2/4 and TLR9 in the ER.
Further differences in interaction between TLRs and PRAT4A were revealed by functional complementation of PRAT4A À/À cells with PRAT4A-M145K. Despite the impaired association of PRAT4A-M145K with TLR2, PRAT4A-M145K was able to complement cell-surface expression (almost fully) and responses of TLR2 (partially) (Figs 4B and 5A ). On the other hand, PRAT4A-M145K weakly, if at all, associated with TLR4, and only slightly rescues TLR4 responses ( Figs 4B and 5B). TLR4 interacts with PRAT4A more robustly than TLR2 (Figs 1 and 2B ). Such strong interaction may be required for cell-surface expression of TLR4/MD-2. By contrast, weak interaction seems to be sufficient for cell-surface expression of TLR2. Cell-surface expression of TLR2 on BMDCs is much higher than TLR4/MD-2 (Fig. 4B) . Cell-surface expression of TLR4 may be negatively regulated and a large amount of PRAT4A may be required for TLR4 trafficking to the cell surface. In this regard, TLR4 would be more sensitive than TLR2 to a change in PRAT4A such as M145K-like mutation or a decrease in the amount of PRAT4A protein.
In response to Pam3CSK4, PRAT4A-M145K only partially complemented the production of IL-6, IL-12 and TNF-a, whereas PRAT4A-M145K almost fully complemented RANTES production (Fig. 5A ). TLR2 requires TLR1 for ) or CpG-B (10 and 100 nM). Gray and filled bars show stimulation at lower and higher dose, respectively. After 24 h stimulation, supernatants were collected and cytokine production (ng/ml) was determined by ELISA. Results are represented by the mean value with standard deviation from triplicate well. recognition of Pam3CSK4 (17) . Interestingly, Pam3CSK4 response is completely abolished in mice lacking TLR2, but partially in those lacking TLR1 (17) . Pam3CSK4 is likely to activate both TLR2/1-dependent responses and TLR2-dependent but TLR1-independent responses. Since PRAT4A was required for the response of TLR1 (7), PRAT4A-M145K may affect the cell-surface expression of TLR1. Despite that PRAT4A-M145K almost fully complemented cell-surface expression of TLR2 (Fig. 4B) , production of IL-6, IL-12 and TNF-a by Pam3CSK4 stimulation was impaired (Fig. 5A) . This might be due to impaired expression of TLR1. By contrast to IL-6, IL-12 and TNF-a production, RANTES production in response to Pam3CSK4 was almost fully recovered, showing correlation with TLR2 expression (Fig. 4B) . RANTES production may be inducible with TLR1-independent and TLR2-dependent response to Pam3CSK4. To address this possibility, it is important to study cell-surface expression of TLR1 in PRAT4A-deficient dendritic cells complemented with PRAT4A-M145K. This experiment is currently under way.
Despite that TLR9 was able to associate with PRAT4A-M145K, abolished TLR9 responses in PRAT4A
À/À cells were not rescued by expression of PRAT4A-M145K (Figs 5C and 6). Physical interaction detected by biochemical means does not necessarily correlate with the functional rescue of TLR9. In addition to physical interaction, PRAT4A may have a role in ligand-induced trafficking. Recently, Unc93B1 was reported to be associated with TLR3/7/9 and deliver TLR7 and TLR9 from the ER to endosome/lysosome upon ligand stimulation (18, 19) . Although over-expressed PRAT4A resides in the ER (7), it is possible that PRAT4A delivers TLR9 as Unc93B1 does. The subcellular distribution of wt and mutant PRAT4As in the steady state and upon CpG-B stimulation is currently being studied. It is also interesting to study physical association between TLR9 and Unc93B1 in PRAT4A À/À cells and those expressing PRAT4A-M145K. We studied three non-synonymous PRAT4A SNPs, one of which, M145K, revealed that a single-nucleotide substitution showed impaired responses in a variety of TLRs. PRAT4A-M145K homozygote or heterozygote, if any, is likely to cause disadvantage in defense responses against infectious diseases. It is of note that sensitivity to the M145K mutation varied between TLRs. Whereas cell-surface expression of TLR2 is rather resistant to this mutation, TLR9 trafficking was completely abolished by the M145K mutation. PRAT4A-M145K mutation may not only impair the strength of combined TLR responses but also change the relative activity of each TLRs. Synergistic stimulation of TLR4 and TLR9 is known to be potent in driving T h 1 response (20) , whereas TLR2 is known to be able to induce T h 2 responses (21, 22) , depending on the nature of the TLR2 ligands. PRAT4A-M145K might influence T h 1-T h 2 balance. According to the SNP databases, the ongoing study determining a frequency of human SNPs has not found PRAT4A-M145K heterozygote or homozygote yet. By contrast, Heterozygote for PRAT4A-R95L allele was found at a frequency of 3.8% in African American population, and heterozygote for PRAT4A-S231I allele was found at a frequency of 2.2-6.7% in Asian population but was found at a frequency of ;33% in European population and 43% in Sub-Saharan African population. Very rare frequency of PRAT4A-M145K mutation may be explained by the present results showing that PRAT4A-M145K mutation drastically impaired TLR responses.
The present study clearly demonstrates that only one base substitution in the PRAT4A allele was able to change responsiveness of multiple TLRs and the relative activity of each TLR. TLRs are known to have a pathogenic role in a variety of diseases including infectious diseases, endotoxin shock and autoimmune diseases. 
